C07K 14/555
Interferons [ifn]
Official title: Interferons [IFN]
C07K14/555 (Interferons [ifn]) appears on 1,303 US grants and 1,526 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,303
- Published applications
- 1,526
- Assignees
- 708
- Inventors
- 2,836
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 5 | 0 |
| 1977 | 4 | 0 |
| 1978 | 1 | 0 |
| 1979 | 3 | 0 |
| 1980 | 5 | 0 |
| 1981 | 15 | 0 |
| 1982 | 11 | 0 |
| 1983 | 9 | 0 |
| 1984 | 25 | 0 |
| 1985 | 14 | 0 |
| 1986 | 11 | 0 |
| 1987 | 26 | 0 |
| 1988 | 29 | 0 |
| 1989 | 28 | 0 |
| 1990 | 25 | 0 |
| 1991 | 19 | 0 |
| 1992 | 17 | 0 |
| 1993 | 13 | 0 |
| 1994 | 15 | 0 |
| 1995 | 18 | 0 |
| 1996 | 23 | 0 |
| 1997 | 22 | 0 |
| 1998 | 35 | 0 |
| 1999 | 33 | 0 |
| 2000 | 26 | 0 |
| 2001 | 31 | 6 |
| 2002 | 26 | 25 |
| 2003 | 23 | 57 |
| 2004 | 22 | 55 |
| 2005 | 17 | 52 |
| 2006 | 21 | 54 |
| 2007 | 31 | 86 |
| 2008 | 34 | 73 |
| 2009 | 64 | 57 |
| 2010 | 40 | 58 |
| 2011 | 36 | 62 |
| 2012 | 35 | 47 |
| 2013 | 36 | 43 |
| 2014 | 30 | 76 |
| 2015 | 51 | 57 |
| 2016 | 38 | 59 |
| 2017 | 39 | 55 |
| 2018 | 40 | 48 |
| 2019 | 36 | 59 |
| 2020 | 36 | 71 |
| 2021 | 31 | 71 |
| 2022 | 35 | 68 |
| 2023 | 29 | 77 |
| 2024 | 36 | 88 |
| 2025 | 33 | 65 |
| 2026 | 21 | 57 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Targeting of human interferon antagonists22 Sep 2026US 12,741,998 B2Centre Hospitalier Regional Universitaire De Montpellier
- Treatment using cytokine encoding RNA18 Aug 2026US 12,708,643 B2BioNTech SE
- Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment18 Aug 2026US 12,709,737 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Pegylated porcine interferon and methods of use thereof16 Jun 2026US 12,653,897 B2Ambrx, Inc.
- Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 216 Jun 2026US 12,655,186 B2Orionis Biosciences BV
- Recombinant expression vector for interferon-beta secretion and attenuated salmonella strain transformed by means of same8 Oct 2026US 2026/0306554 A1The Industry & Academic Cooperation in Chungnam National University (IAC)
- Targeted engineered interferon and uses thereof8 Oct 2026US 2026/0308221 A1Orionis Biosciences BV
- Genetically engineered cd4 t-cells for in situ synthesis of proteins8 Oct 2026US 2026/0308515 A1SRI International
- Inducible programmed cell death-1 (pd1)-cytokine chimera for potentiated immune cell function24 Sep 2026US 2026/0284108 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Target protein expression platform using viral nucleocapsid10 Sep 2026US 2026/0265307 A1University-Industry Foundation, Yonsei University
Most cited
By later US patents
- N-terminally chemically modified protein compositions and methods378US 5,824,784 AAmgen Inc. · 1998
- Methods and compositions for polypeptide engineering338US 6,586,182 B1Maxygen, Inc. · 2003
- Human recombinant interleukin-2 muteins297US 4,518,584 ACetus Corporation · 1985
- Covalently linked polypeptide cell modulators269US 4,935,233 AG. D. Searle & Co. · 1990
- Preparation of an activated polymer ester for protein conjugation269US 5,281,698 ACetus Oncology Corporation · 1994